BACKGROUND AND PURPOSE: Perinatal stroke is a common cause of life-long neurobehavioral compromise. Mesenchymal stromal cells (MSCs) and EPO (erythropoietin) have each demonstrated short-term benefit with delayed administration after stroke, and combination therapy may provide the most benefit. The purpose of this study is to determine the long-term histological and functional efficacy of enhanced, intranasal stem cell therapy (MSC preexposed to EPO) compared with standard MSC or multidose systemic EPO. METHODS: Transient middle cerebral artery occlusion or sham surgery was performed in postnatal day (P) 10 Sprague-Dawley rats, who were treated with single-dose intranasal MSC, MSC preexposed to EPO (MSC/EPO), multidose systemic EPO (EPO3; 1000 u/kg per dose×3 every 72 hours), or cell-conditioned media on P13 (day 3 [P13-P19] for EPO), or on P17 (day 7 [P17-P23] for EPO). At 2 months of age, animals underwent novel object recognition, cylinder rearing, and open field testing to assess recognition memory, sensorimotor function, and anxiety in adulthood. RESULTS: MSC, MSC/EPO, and EPO3 improved brain volume when administered at 3 or 7 days after middle cerebral artery occlusion. MSC/EPO also enhanced long-term recognition memory with either day 3 or day 7 treatment, but EPO3 had the most long-term benefit, improving recognition memory and exploratory behavior and reducing anxiety. CONCLUSIONS: These data suggest that single-dose MSC/EPO and multidose systemic EPO improve long-term neurobehavioral outcomes even when administration is delayed, although EPO was the most effective treatment overall. It is possible that EPO represents a final common pathway for improved long-term repair, although the specific mechanisms remain to be determined.
BACKGROUND AND PURPOSE: Perinatal stroke is a common cause of life-long neurobehavioral compromise. Mesenchymal stromal cells (MSCs) and EPO (erythropoietin) have each demonstrated short-term benefit with delayed administration after stroke, and combination therapy may provide the most benefit. The purpose of this study is to determine the long-term histological and functional efficacy of enhanced, intranasal stem cell therapy (MSC preexposed to EPO) compared with standard MSC or multidose systemic EPO. METHODS: Transient middle cerebral artery occlusion or sham surgery was performed in postnatal day (P) 10 Sprague-Dawley rats, who were treated with single-dose intranasal MSC, MSC preexposed to EPO (MSC/EPO), multidose systemic EPO (EPO3; 1000 u/kg per dose×3 every 72 hours), or cell-conditioned media on P13 (day 3 [P13-P19] for EPO), or on P17 (day 7 [P17-P23] for EPO). At 2 months of age, animals underwent novel object recognition, cylinder rearing, and open field testing to assess recognition memory, sensorimotor function, and anxiety in adulthood. RESULTS: MSC, MSC/EPO, and EPO3 improved brain volume when administered at 3 or 7 days after middle cerebral artery occlusion. MSC/EPO also enhanced long-term recognition memory with either day 3 or day 7 treatment, but EPO3 had the most long-term benefit, improving recognition memory and exploratory behavior and reducing anxiety. CONCLUSIONS: These data suggest that single-dose MSC/EPO and multidose systemic EPO improve long-term neurobehavioral outcomes even when administration is delayed, although EPO was the most effective treatment overall. It is possible that EPO represents a final common pathway for improved long-term repair, although the specific mechanisms remain to be determined.
Authors: Ruggero Spadafora; Fernando F Gonzalez; Nikita Derugin; Michael Wendland; Donna Ferriero; Patrick McQuillen Journal: Dev Neurosci Date: 2010-05-04 Impact factor: 2.984
Authors: Cindy T J van Velthoven; R Ann Sheldon; Annemieke Kavelaars; Nikita Derugin; Zinaida S Vexler; Hanneke L D M Willemen; Mirjam Maas; Cobi J Heijnen; Donna M Ferriero Journal: Stroke Date: 2013-03-28 Impact factor: 7.914
Authors: Sung Shin Kim; Kyung-Hoon Lee; Dong Kyung Sung; Jae Won Shim; Myo Jing Kim; Ga Won Jeon; Yun Sil Chang; Won Soon Park Journal: J Korean Med Sci Date: 2008-06 Impact factor: 2.153
Authors: Vanessa Donega; Cindy T J van Velthoven; Cora H Nijboer; Frank van Bel; Martien J H Kas; Annemieke Kavelaars; Cobi J Heijnen Journal: PLoS One Date: 2013-01-03 Impact factor: 3.240
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329
Authors: Jana Krystofova Mike; Katherine Y Wu; Yasmine White; Praneeti Pathipati; Blaise Ndjamen; Rachel S Hutchings; Courtney Losser; Christian Vento; Kimberly Arellano; Oona Vanhatalo; Samuel Ostrin; Christine Windsor; Janica Ha; Ziad Alhassen; Brian D Goudy; Payam Vali; Satyan Lakshminrusimha; Jogarao V S Gobburu; Janel Long-Boyle; Peggy Chen; Yvonne W Wu; Jeffrey R Fineman; Donna M Ferriero; Emin Maltepe Journal: Dev Neurosci Date: 2022-05-19 Impact factor: 3.421